BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//MedNet - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MedNet
X-ORIGINAL-URL:https://mednetus.net
X-WR-CALDESC:Events for MedNet
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250301
DTEND;VALUE=DATE:20250302
DTSTAMP:20260423T102008
CREATED:20250620T071506Z
LAST-MODIFIED:20250620T072653Z
UID:10000013-1740787200-1740873599@mednetus.net
SUMMARY:Ocular Surface Disease: Pathophysiology\, Evaluation\, Management with Topical Agents\, and Neuromodulation
DESCRIPTION:March 8\, 2025 \n\n\nTake Me to the Event Registration\n\n\n\nEVENT Summary \nDates \nSaturday\, March 8\, 2025\, 10:00 AM ET\, 9:00 AM CT\, 8:00 AM MT\, and 7:00 AM PT \nLocation \nVirtual \nTarget Audience \nOphthalmologists\, optometrists\, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with ocular surface disease \nFormat \nZoom Webinar \nCredits \n1.25 / AMA PRA Category 1 Credit(s)TM\n1.25 / COPE CE Credits \nCost \nFree \nProgram Description \nClick to Go to the Event Registration \nThis program will provide up-to-date\, evidence-based information on pathophysiology\, evaluation\, topical agents\, and neuromodulation in managing OSD. The activity will focus on: \n\nPathophysiology – Normal ocular surface physiology\, including the role of the lacrimal functional unit in stimulating the lacrimal gland\, meibomian glands\, and goblet cells.\nRisk factors for OSD – Contact lens wear\, ocular surgery\, extensive digital device use\, and eye makeup.\nEvaluation – Symptom questionnaires\, tear breakup time\, tear volume assessment\, and ocular surface staining\nManagement of OSD with Artificial Tears – Artificial tear formulations and benefits in managing different dry eye sub-types\n\nActive and inactive ingredients\, including the role of inactive ingredients in optimizing delivery and retention time.\nPreserved vs preservative-free (unit dose vs multi-dose dispensing methods)\nLipid-enhanced vs. non-lipid-enhanced.\nThe efficacy and safety profile of short-term and chronic treatment options for inflammatory dry eye.\n\n\nNeuromodulation in OSD – Neural network that monitors the ocular surface environment and regulates tear secretion.\n\nAfferent sensory fibers in the nasal mucosa and ocular surface (nicotinic muscarinic receptors and TRP receptors).\nEfferent parasympathetic pathways and targets (lacrimal gland\, meibomian glands\, and goblet cells.\nNeurotrophic Keratopathy (NK) – Clinically\, stage 1 NK is similar to moderate-to-severe dry eye disease (DED) or many other epitheliopathies\nCenegermin is a recombinant human nerve growth factor (rh-NGF) that supports corneal reinnervation.\n\n\n\nAgenda \n• Overview of the pathophysiology\, risk factor\, and evaluation of ocular surface disease (OSD) – Sarah B. Sunshine\, MD \n• Discuss the data on artificial tear formulations and neuromodulation in managing OSD – TBD \nIntended Audience \nOphthalmologists\, optometrists\, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with ocular surface disease \nCommercial Supporter \nSupported by an unrestricted educational grant from Dompé US Inc. \nLearning Objectives \nSummarize the pathophysiology\, risk factor\, and evaluation of ocular surface disease\nInterpret data on artificial tear formulations and neuromodulation in managing ocular surface disease \n\n\n\n\n\n\n\n\n\nAccredited Providers \nAmedco and MedNet have collaborated to design and execute this activity. \n      \nJoint Accreditation Statement \nIn support of improving patient care\, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163. \nPhysicians (ACCME) Credit Designation \nAmedco LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nOptometrists Credit \nThis activity\, COPE Activity Number 130237\, is accredited by COPE for continuing education for optometrists. \nMedNet designates this activity for a maximum of 1.25 COPE credits. \nAdditional Credit Information \nPhysician Assistants\nPAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. \nNurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.25 hours. \nDisclosures of Relationships with Ineligible Companies Policy \nIn accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education\, all faculty\, planning committee members\, and other individuals\, who are in a position to control content\, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance\, scientific objectivity\, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated. \nPlanners’ and Managers’ Disclosures \nAll relevant relationships have been reviewed and mitigated. \nOff-Label Disclosure Statement \nFaculty members are required to inform the audience when they are discussing off-label\, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity. \n\nFaculty \n \nSarah B. Sunshine\, MD\nAssistant Professor\nOphthalmology\, University of Maryland and Greenebaum Comprehensive Cancer\nBaltimore\, MD \nInstructions/Technical Requirements \nHardware: An internet-enabled computer\, smartphone\, tablet\, or other mobile device with audio and internet capabilities. \nSoftware: Installation of software like Zoom may be necessary. \nCost \nThere are no fees for participating and receiving CME and COPE credit for this activity. \nContact \nBrian Waggoner\nProgram Manager\nMedNet\nbrianw@mmhus.net
URL:https://mednetus.net/event/ocular-surface-disease-pathophysiology-evaluation-management-with-topical-agents-and-neuromodulation-2/
CATEGORIES:Live Program
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/yni3h2klcmaj-800x450-1.jpg
END:VEVENT
END:VCALENDAR